PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The Basel-based pharmaceutical giant Novartis has secured the patent rights for US company bluebird bio’s Lentiviral Vector platform. It provides a basis on which to develop treatment methods for cancer.
Novartis will use the licensing rights to develop and commercialise chimeric antigen receptor T-cell (CAR T) therapies, announced a bluebird bio statement. CAR T isolates immune T-cells, which are then re-programmed with the implantation of a CAR molecule. They are then injected into patients to fight cancer.
bluebird bio developed its Lentiviral Vector platform to facilitate such re-programming. It can be used in both gene therapy and in the development of cancer medications. Novartis intends to use the technology for aspects including the further development of its CTL019 compound.
The licensing agreement is global and non-exclusive. Novartis will make an upfront payment to bluebird as well as milestone and royalty payments. The value of the transaction has not been disclosed.